These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 15297168)

  • 21. A phase-I study evaluating the combination of pegylated liposomal doxorubicin and paclitaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracycline.
    Hong RL; Lin CH; Chao TY; Kao WY; Wang CH; Hsieh RK; Hwang WS
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):847-53. PubMed ID: 17609947
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut).
    du Bois A; Pfisterer J; Burchardi N; Loibl S; Huober J; Wimberger P; Burges A; Stähle A; Jackisch C; Kölbl H; ;
    Gynecol Oncol; 2007 Dec; 107(3):518-25. PubMed ID: 17910981
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer.
    Mirchandani D; Hochster H; Hamilton A; Liebes L; Yee H; Curtin JP; Lee S; Sorich J; Dellenbaugh C; Muggia FM
    Clin Cancer Res; 2005 Aug; 11(16):5912-9. PubMed ID: 16115933
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The use of cod liver oil by patients receiving pegylated liposomal doxorubicin is associated with a lack of severe palmar-plantar erythrodysesthesia.
    Kanis M; Kesterson JP; Lele S
    Eur J Gynaecol Oncol; 2009; 30(4):387-8. PubMed ID: 19761128
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized trial of two different doses of pyridoxine in the prevention of capecitabine-associated palmar-plantar erythrodysesthesia.
    Chalermchai T; Tantiphlachiva K; Suwanrusme H; Voravud N; Sriuranpong V
    Asia Pac J Clin Oncol; 2010 Sep; 6(3):155-60. PubMed ID: 20887495
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Plantar-palmar erythrodysesthesia. A new and relatively frequent side effect in antineoplastic treatment].
    Risum S; Langer SW
    Ugeskr Laeger; 2003 Aug; 165(33):3161-2. PubMed ID: 12968412
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incidence of palmar-plantar erythrodysesthesia in pretreated and unpretreated patients receiving pegylated liposomal doxorubicin.
    Miolo G; Baldo P; Bidoli E; Lombardi D; Scalone S; Sorio R; Veronesi A
    Tumori; 2009; 95(6):687-90. PubMed ID: 20210230
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion.
    Fabian CJ; Molina R; Slavik M; Dahlberg S; Giri S; Stephens R
    Invest New Drugs; 1990 Feb; 8(1):57-63. PubMed ID: 2345070
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pegylated liposomal doxorubicin (Lipo-Dox) for platinum-resistant or refractory epithelial ovarian carcinoma: a Taiwanese gynecologic oncology group study with long-term follow-up.
    ; Chou HH; Wang KL; Chen CA; Wei LH; Lai CH; Hsieh CY; Yang YC; Twu NF; Chang TC; Yen MS
    Gynecol Oncol; 2006 Jun; 101(3):423-8. PubMed ID: 16325239
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histologic patterns of polyethylene glycol-liposomal doxorubicin-related cutaneous eruptions.
    Cady FM; Kneuper-Hall R; Metcalf JS
    Am J Dermatopathol; 2006 Apr; 28(2):168-72. PubMed ID: 16625083
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pyridoxine as prophylactic therapy for palmar-plantar erythrodysesthesia associated with administration of pegylated liposomal doxorubicin (caelyx): a single-center experience.
    Rossi D; Catalano G
    Oncology; 2007; 73(3-4):277-8. PubMed ID: 18424894
    [No Abstract]   [Full Text] [Related]  

  • 32. Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia.
    Lopez AM; Wallace L; Dorr RT; Koff M; Hersh EM; Alberts DS
    Cancer Chemother Pharmacol; 1999; 44(4):303-6. PubMed ID: 10447577
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of pegylated liposomal doxorubicin (Doxil) as second-line chemotherapy of squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.
    Rose PG; Blessing JA; Lele S; Abulafia O
    Gynecol Oncol; 2006 Aug; 102(2):210-3. PubMed ID: 16478630
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.
    Autier J; Escudier B; Wechsler J; Spatz A; Robert C
    Arch Dermatol; 2008 Jul; 144(7):886-92. PubMed ID: 18645140
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma.
    Jakubowiak AJ; Kendall T; Al-Zoubi A; Khaled Y; Mineishi S; Ahmed A; Campagnaro E; Brozo C; Braun T; Talpaz M; Kaminski MS
    J Clin Oncol; 2009 Oct; 27(30):5015-22. PubMed ID: 19738129
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts.
    von Moos R; Thuerlimann BJ; Aapro M; Rayson D; Harrold K; Sehouli J; Scotte F; Lorusso D; Dummer R; Lacouture ME; Lademann J; Hauschild A
    Eur J Cancer; 2008 Apr; 44(6):781-90. PubMed ID: 18331788
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer.
    Rose PG
    Oncologist; 2005 Mar; 10(3):205-14. PubMed ID: 15793224
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Liposomal doxorubicin and palmoplantar erythrodysesthesia].
    Tomb R; Stephan F; Halaby G
    Ann Dermatol Venereol; 2003 Nov; 130(11):1057-8. PubMed ID: 14724543
    [No Abstract]   [Full Text] [Related]  

  • 39. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
    Pradermdee P; Manusirivithaya S; Tangjitgamol S; Thavaramara T; Sukwattana P
    J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG).
    Crump M; Baetz T; Couban S; Belch A; Marcellus D; Howson-Jan K; Imrie K; Myers R; Adams G; Ding K; Paul N; Shepherd L; Iglesias J; Meyer R
    Cancer; 2004 Oct; 101(8):1835-42. PubMed ID: 15386331
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.